{"id":72893,"date":"2026-07-05T10:55:17","date_gmt":"2026-07-05T10:55:17","guid":{"rendered":"https:\/\/trialcontact.com\/?p=72893"},"modified":"2026-07-05T10:59:22","modified_gmt":"2026-07-05T10:59:22","slug":"can-a-natural-nasal-spray-block-dust-mite-allergy-flare-ups-inside-the-acaray-clinical-trial","status":"publish","type":"post","link":"https:\/\/trialcontact.com\/?p=72893","title":{"rendered":"Can a Natural Nasal Spray Block Dust Mite Allergy Flare-Ups? Inside the ACARAY Clinical Trial"},"content":{"rendered":"\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

\n\n

If you\u2019ve ever woken up congested, sneezed nonstop through the night, or dealt with scratchy, watery eyes all year long, you\u2019re likely familiar with allergic rhinitis. Millions of people worldwide battle persistent nasal allergies triggered by everyday indoor triggers\u2014and dust mites rank among the most relentless culprits. Unlike pollen, which only surges for a few months each spring or fall, dust mites live year-round in bedding, carpets, couches, and soft furnishings, creating constant low-grade allergy distress for sensitive people.<\/p>\n\n\n\n

Traditional go-to fixes for dust mite allergies follow two main paths: long-term allergen immunotherapy (allergy shots) to rewire your immune system, or fast-acting symptom drugs like oral antihistamines and steroid nasal sprays. But these standard treatments come with drawbacks many patients find frustrating. Some people dislike daily pill routines or worry about long-term topical steroid use. Others seek gentler, drug-free alternatives to manage mild-to-moderate allergy symptoms, especially when their flare-ups aren\u2019t severe enough to warrant heavy medication. Yet reliable, rigorous research on natural nasal allergy barrier sprays remains surprisingly limited\u2014leaving allergy sufferers guessing whether plant-based nasal products actually deliver real, measurable relief.<\/p>\n\n\n\n

This knowledge gap is exactly why French natural healthcare brand Puressentiel launched the ACARAY Study, formally titled Evaluation of the Clinical Efficacy of PURESSENTIEL Allergy Protection Nasal Spray (SNPA\u00ae) in House Dust Mite Allergic Rhinitis, this small but carefully designed clinical trial sets out to answer a straightforward, consumer-centric question: Can a plant-derived protective nasal spray create a physical barrier in the nose that blunts dust mite allergy reactions, compared to plain saline water?<\/p>\n\n\n\n

This article breaks down everything everyday allergy sufferers need to know about the ACARAY trial\u2014starting with the basics of dust mite allergies, explaining how the test nasal spray works in theory, walking through the trial\u2019s simple core design without dense medical jargon, and unpacking what meaningful results could mean for anyone tired of year-round mite-induced congestion and sneezes.<\/p>\n\n\n\n

What Is Dust Mite Allergic Rhinitis, and Why It\u2019s Such a Persistent Nuisance
Before diving into the trial itself, it helps to understand exactly what happens inside your body when dust mites trigger an allergic reaction. Allergic rhinitis is an overactive immune response to harmless environmental particles called allergens. Dust mites are microscopic arachnids that feed on shed human skin cells; their tiny fecal particles and body fragments float through household air and stick to soft surfaces. When you inhale these fragments, your immune system mistakenly labels them as dangerous invaders.<\/p>\n\n\n\n

For people with dust mite sensitivity, exposure sparks a cascade of inflammatory chemicals like histamine inside the nasal lining. This reaction creates the classic set of symptoms known as rhino-conjunctivitis: repeated sneezing, runny or stuffy nose, post-nasal drip, itchy nasal passages, red, burning eyes, and mild sinus pressure. Unlike pollen allergies (seasonal rhinitis), dust mite reactions are perennial\u2014meaning symptoms linger 12 months a year, often worsening overnight when you lie on mite-infested pillows and mattresses.<\/p>\n\n\n\n

Many patients report mild to moderate daily symptoms that don\u2019t fully justify powerful prescription treatments, yet still disrupt sleep, work focus, and daily comfort. Standard medical guidance offers three primary management strategies:<\/p>\n\n\n\n

    \n
  1. Allergen avoidance: Regular deep cleaning, mattress\/ pillow dust-mite covers, low-humidity bedrooms, and removing fabric carpets. This reduces exposure but rarely eliminates mites entirely.<\/li>\n\n\n\n
  2. Symptom medication: Over-the-counter or prescription antihistamine tablets and steroid nasal sprays that suppress inflammation after allergy exposure has already begun.<\/li>\n\n\n\n
  3. Allergen immunotherapy: Long-term shot or sublingual tablet treatment that slowly retrains the immune system to tolerate mites, reserved for people with severe, unmanageable symptoms.<\/li>\n<\/ol>\n\n\n\n

    A large portion of mite allergy patients actively seek non-pharmaceutical, natural barrier products to add to their routine. The core idea behind barrier nasal sprays is simple: coat the delicate nasal tissue with a protective film that traps allergen particles before they can touch immune cells and spark inflammation. Saline nasal rinses and sprays already work by washing irritants away, but Puressentiel\u2019s SNPA\u00ae Allergy Protection Nasal Spray adds proprietary plant-based ingredients designed to form a longer-lasting protective layer\u2014something plain salt water cannot replicate. Until the ACARAY trial launched, there was little formal clinical data proving whether this barrier effect actually reduces measurable allergy symptoms during controlled mite exposure.<\/p>\n\n\n\n

    The Core Goal of the ACARAY Trial: Testing a Natural Nasal Barrier Against Dust Mites
    Sponsored entirely by Puressentiel, a French natural health brand focused on essential oil and plant-based wellness products, the ACARAY trial is a prevention-focused interventional study. Its central research hypothesis is easy to grasp for non-medical readers: Pre-treating the nasal passages with SNPA\u00ae before intentional dust mite exposure will significantly lower allergic rhinitis symptoms, when measured against pre-treatment with standard saline spray (the placebo comparison group).<\/p>\n\n\n\n

    The trial splits its goals into one primary main objective and two secondary supporting objectives, both centered on patient comfort and physical nasal function:
    Primary Objective
    Measure the difference in overall rhino-conjunctivitis symptom severity after a standardized dust mite nasal challenge test, comparing participants who used SNPA\u00ae beforehand versus those who used saline placebo. Researchers rely on a validated allergy symptom scoring system to quantify sneezing, congestion, itchiness, and eye irritation across four hours post-exposure. This score difference is the trial\u2019s key benchmark for proving the spray\u2019s protective value.<\/p>\n\n\n\n

    Crucially, the trial is not designed to deliver direct personal health benefits to the 20 volunteer participants. Every volunteer undergoes controlled, intentional mite exposure that will trigger temporary allergy flares. The value of the research lies in its wider public impact: if results favor SNPA\u00ae, healthcare providers will gain credible clinical evidence to recommend a drug-free natural nasal barrier as an add-on allergy management tool for mild-to-moderate dust mite rhinitis patients. The only foreseeable risk for volunteers is temporary, self-resolving allergy symptoms from the standardized nasal challenge test, with no permanent side effects expected.<\/p>\n\n\n\n

    Who Can Join the ACARAY Trial? Clear, Fair Eligibility Rules
    The trial enrolls exactly 20 adult volunteers at a single study site: the Arnaud de Villeneuve University Hospital in Montpellier, France, within the hospital\u2019s Allergology and Respiratory Thoracic Oncology division. All participants are existing patients who previously visited the hospital\u2019s allergy clinic with confirmed dust mite rhinitis, creating a consistent, relevant test group.<\/p>\n\n\n\n

    Basic Rules to Qualify (Inclusion Criteria)<\/p>\n\n\n\n

      \n
    1. Aged 18 years or older (no minors allowed)<\/li>\n\n\n\n
    2. Confirmed perennial dust mite rhino-conjunctivitis diagnosed at least 12 months before signing up<\/li>\n\n\n\n
    3. Asthma patients may join only if their asthma is fully stable and well-controlled<\/li>\n\n\n\n
    4. Willing to pause all allergy medications ahead of testing: antihistamines for 7 days, steroid nasal sprays for a full month<\/li>\n\n\n\n
    5. Hold French health insurance coverage and speak fluent French to understand trial paperwork and consent forms<\/li>\n\n\n\n
    6. Provide voluntary, written informed consent to take part in all study visits and testing procedures<\/li>\n<\/ol>\n\n\n\n

      The strict washout period for allergy drugs eliminates confounding variables: researchers need to isolate the spray\u2019s effects without antihistamines or steroids masking natural immune reactions to dust mites.<\/p>\n\n\n\n

      How the ACARAY Trial Works: Simple Crossover Double-Blind Study Design
      For everyday readers, clinical trial terminology often sounds intimidating, but the ACARAY study\u2019s structure is straightforward to unpack. It uses a randomized, double-blind, placebo-controlled crossover design\u2014the gold standard for testing consumer wellness products, because it eliminates bias from both participants and medical staff running the tests.<\/p>\n\n\n\n

      All data collected during these time points feeds directly into the trial\u2019s primary and secondary outcome measurements, tracking symptom severity and nasal breathing capacity over time.<\/p>\n\n\n\n

      What Are the Two Test Interventions? SNPA\u00ae Barrier Spray vs. Saline Placebo
      The two devices under evaluation are both nasal sprays, but their core functions differ dramatically:
      Active Intervention: Puressentiel Allergy Protection Nasal Spray (SNPA\u00ae)
      Classified as a medical device rather than a pharmaceutical drug, this plant-based nasal spray is formulated to create a thin, adhesive protective film on the nasal cavity\u2019s inner lining. The intended mechanism is physical barrier protection: mite allergen particles stick to the film instead of binding to nasal immune cells, which stops the inflammatory histamine cascade before it starts. Each volunteer receives two sprays per nostril 30 minutes prior to dust mite exposure during their assigned SNPA visit.<\/p>\n\n\n\n

      Placebo Intervention: 0.65% Isotonic Saline Nasal Spray
      Ordinary saltwater nasal spray serves as the neutral control. Saline washes loose irritants out of nasal passages temporarily but cannot form a lasting protective layer. It matches the SNPA spray\u2019s delivery format (same spray bottle, identical dosing of two sprays per nostril) to uphold the double-blind study rules\u2014volunteers cannot visually or texturally tell the two sprays apart during testing.<\/p>\n\n\n\n

      Timeline, Compensation, and Expected Trial Milestones
      The ACARAY trial launched with an estimated start date of November 1, 2025, and plans to finish all volunteer testing procedures by September 30, 2026. Full data analysis and final study wrap-up are projected to conclude by February 1, 2027. At the time of this writing (2026), the trial status is listed as \u201cNot Yet Recruiting,\u201d meaning hospital allergy staff are still preparing study protocols and screening eligible patients to join the volunteer group.<\/p>\n\n\n\n

      Participants receive financial compensation up to \u20ac500 for completing both hospital visits and all follow-up assessments, covering travel costs, time off work, and minor inconvenience from temporary allergy flare-ups triggered by the mite challenge test. The trial does not allow volunteers to join other clinical studies seven days before enrollment or seven days after their final study visit, to avoid mixing unrelated treatment data that could skew ACARAY\u2019s results.<\/p>\n\n\n\n

      No independent data monitoring committee (DMC) oversees this small trial, as the procedures carry minimal serious risk, and all testing is conducted by experienced hospital allergy specialists following established European allergen challenge safety guidelines. The trial also falls outside U.S. FDA drug or medical device regulation, as it is a European single-center study run under French public health medical research laws.<\/p>\n \n\n\n

      Why This Trial Matters for Every Dust Mite Allergy Sufferer
      Millions of people around the world rely on natural wellness products to manage mild, persistent allergy symptoms, yet consumer-facing barrier nasal sprays often lack rigorous clinical trial validation. Most product marketing relies on anecdotal user reviews rather than standardized, controlled allergen exposure testing like the ACARAY trial uses.<\/p>\n\n\n\n

      If ACARAY\u2019s final data shows consistent, meaningful reductions in symptom scores and better preserved nasal airflow after SNPA\u00ae use, three key real-world takeaways will emerge for allergy patients and healthcare providers:<\/p>\n\n\n\n

        \n
      1. A drug-free, plant-based nasal barrier spray could be recommended as a preventive daily tool for people with year-round dust mite rhinitis, used before bedtime or cleaning routines to block mite allergen exposure.<\/li>\n\n\n\n
      2. Patients sensitive to oral antihistamine side effects (drowsiness, dry mouth) or hesitant to use long-term nasal steroids will gain a clinically supported alternative to add to their allergy management toolkit.<\/li>\n\n\n\n
      3. Allergy specialists will have peer-reviewable trial evidence to discuss natural barrier sprays with patients, rather than dismissing plant-based nasal products as untested wellness fads.<\/li>\n<\/ol>\n\n\n\n

        Even if results show only mild benefits from SNPA\u00ae, the trial still fills a critical research gap: it creates a formal benchmark for future natural nasal barrier product studies, setting a template for standardized mite nasal challenge testing for consumer wellness nasal sprays.<\/p>\n\n\n\n

        These limitations do not invalidate the study\u2019s value\u2014they simply frame its scope as a focused proof-of-concept trial to confirm whether SNPA\u2019s barrier mechanism delivers measurable acute protection against concentrated dust mite allergen exposure. Positive results would pave the way for larger, longer follow-up trials covering broader patient groups and real-world home use scenarios.<\/p>\n\n\n\n

        Conclusion
        For anyone tired of year-round sneezing, congestion, and scratchy eyes caused by invisible household dust mites, the ACARAY clinical trial represents a long-awaited deep dive into whether natural nasal barrier sprays can deliver tangible, clinically proven relief without pharmaceutical drugs. Backed by rigorous double-blind, crossover testing at a leading French university allergy hospital, the small-scale study aims to answer a simple consumer question millions of allergy patients ask every day: Can a plant-based nasal spray create a protective shield that stops dust mite allergy reactions before they start?<\/p>\n\n\n\n

        We will wait for full trial completion in early 2027 to review the final symptom and airflow data. Whatever the outcome, the ACARAY Study advances public knowledge of non-pharmacological allergy management, offering much-needed formal research into a category of wellness products that millions already use without clear clinical validation. If the results favor the SNPA\u00ae protective nasal spray, dust mite allergy sufferers worldwide will gain a new, drug-free preventive option to add to their daily symptom control routine\u2014one backed by standardized hospital allergy testing rather than marketing claims alone.<\/p>\n\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n\n

        <\/p>\n\n\n

        \n\n

        Related Clinical Trials<\/h2>\n

        Anti-Inflammatory Reliever South Africa<\/h4>\n

        This is a Phase 3 single-centre open label randomised controlled trial with two equal sized groups to assess the efficacy of budesonide\/formoterol 80\/4.5 (6-11 years) and 160\/4.5 (12-18 years) compared to the standard of care in reducing asthma exacerbations over 52 weeks. Children and adolescents with a diagnosis of asthma or newly diagnosed with asthma will be screened for eligibility for enrolment. Those who had an asthma exacerbation in the previous year will be randomised 1:1, to either receive budesonide\/formoterol inhaler for both symptom relief and for chronic anti- inflammatory maintenance therapy or the standard of care which is separate inhalers for symptom relief (short acting bronchodilator salbutamol) and chronic maintenance therapy with inhaled corticosteroids (beclomethasone or budesonide) and\/or long-acting beta agonists or montelukast as determined by treating physicians. All asthma exacerbations and clinic\/hospital admissions will be recorded for the duration of the 52-week follow-up. Participants will be followed up at 13, 26, 39 and 52 weeks. The 13- and 39-week visit will be telephonic visits to capture the primary end-point i.e. asthma exacerbations. Adverse events and medication changes data will also be collected. An independent Data and Safety Monitoring Board (DSMB) will be convened for this study with expertise in asthma and asthma clinical trials. The purpose of the DSMB will be to monitor the study for safety and operational futility with pre-defined stopping criteria. In addition, a Trial Steering Committee (TSC) will also provide overall supervision of the trial and ensure the trial is delivered in accordance with ICH-GCP. The TSC has been established with an independent Chair and include additional independent members including an observer early career researcher. Representatives of the Trial Funder (NIHR) and Sponsor (AHRI) will be invited to all TSC meetings.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma<\/h4>\n

        The purpose of this study is to compare the effect of budesonide\/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form<\/h4>\n

        The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called “enterotyping” analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma. The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform<\/h4>\n

        Treating breathlessness could help people with asthma have fewer symptoms and be more physically active. People with asthma report that it is important to deal with breathlessness during physical activity programs, but past research hasn’t focused on this need. The investigators have developed a multicomponent digitally supported intervention targeting breathlessness and physical inactivity. This study will test whether the multicomponent digital supported intervention will help people with asthma. The main question the study aims to answer is: Does the multicomponent digitally supported intervention improve quality of life? Participants will: * Be allocated to the intervention or usual care. Allocation to either group will be random (like tossing a coin). * Attend study visits to complete an assessment involving questionnaires and measurements * Receive telephone calls to ask questions about health * Be invited to take part in an interview to have a conversation about thoughts on participating in the study * Be asked to provide consent to collect information from Services Australia regarding use of health care services and medications<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy<\/h4>\n

        This study evaluates whether adding a spacer device to triple inhaled therapy (ICS\/LABA\/LAMA via pMDI) can reduce acute exacerbations in elderly patients (\u226565 years) with stable chronic airway diseases (COPD or asthma) who are classified as high-risk based on GOLD or GINA guidelines. High risk is defined as \u22651 hospitalization or \u22652 moderate exacerbations in the past 12 months. Despite receiving triple inhaled therapy, these patients often have poor inhaler technique due to age-related limitations. A spacer may improve drug delivery, adherence, and reduce local side effects. In this multicenter, open-label, randomized controlled trial, 380 participants will be assigned to standard therapy with or without a valved spacer. The primary outcome is the 3-month incidence of moderate-to-severe exacerbations. Secondary outcomes include lung function, adherence, inhalation technique, side effects, and patient satisfaction.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma<\/h4>\n

        The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Withdrawal of Dupilumab in Severe Asthma<\/h4>\n

        Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months. Although data showed that safety and efficacy of dupilumab are sustained when treatment is extended up to 3 years, no study has emerged regarding dupilumab discontinuation. This study aims to demonstrate the non-inferiority regarding strategy failure at 24 months of stopping dupilumab (intervention group) compared with its continuation (control group) in controlled asthma patients receiving this drug for at least 3 years.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Prevalence of EILO Among Children With Asthma<\/h4>\n

        The goal of this cross-sectional study is to investigate the prevalence of Exercise Induced Laryngeal Obstruction (EILO) in children with asthma. The hypothesis is that the prevalence will be around 15%, which is higher than the prevalence of 5-8% among the general adolescent population. This is based on the increased prevalence of EILO among adult asthmatics. Participants who are referred for an Exercise Challenge Test will perform an additional Continuous Laryngoscopy during Exercise Test with expiratory FEV1 curves, and fill in the Borg scale for dyspnea, Asthma Control Test, EILODI questionnaire and DISCO-RC questionnaire.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma<\/h4>\n

        This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma. The primary objective is to demonstrate the superiority of DW1807 over DW1807-R2 in improving the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation<\/h4>\n

        The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into CR and PR programmes via an online platform that delivers both exercise prescription and air pollution guidance. Specific objectives are: (1) to determine whether access to real-time air quality data reduces personal pollution exposure (PM2.5, PM10, NO2) during outdoor physical activity in CR\/PR patients and healthy volunteers; (2) to evaluate the usability and acceptability of the platform in a clinical rehabilitation context; (3) to assess the feasibility of the trial design, including recruitment, randomisation, retention, and adherence rates; (4) to measure the impact of the intervention on physical activity levels, health-related quality of life, and cardiovascular biomarkers; and (5) to inform the design and sample size of a future definitive randomised controlled trial.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Reducing Asthma Attacks in Disadvantaged School Children With Asthma<\/h4>\n

        Our UH3 clinical trial, “Reducing Asthma Attacks in Disadvantaged School Children with Asthma,” seeks broad-scale implementation of our effective school-based approach to improve asthma disparities for children, ages 5-12 years, in low-income communities. The investigators will contextualize dissemination and implementation (D\\&I) of our Colorado school-based asthma program (Col-SBAP) that reduces asthma exacerbations and missed school days, while also addressing social determinants of health. Our Better Asthma Control for Kids (BACK) Program will evaluate key metrics identified by diverse stakeholders during this dissemination trial in rural and small metropolitan areas of Colorado. Our clinical trial includes two implementation strategies: our standard Col-SBAP, titled BACK-Standard (BACK-S) and an enhanced community-centered approach, titled Back-Enhanced (BACK-E). These two strategies are designed for sustainable delivery by school asthma navigators and school nurses who coordinate with primary care and community resources. The Exploration, Preparation, Implementation, Sustainment (EPIS) D\\&I framework was applied with community partners during the UG3 planning phase to tailor implementation plans that meet local community needs, resources and priorities (EPIS Phases 1 \\& 2). BACK-S and BACK-E will be delivered from years 1-3 with data collection for implementation and effectiveness outcomes in 4 Colorado regions. In year 4, the investigators will collect data for sustainment outcomes (EPIS phase 3). The investigators will apply the work from EPIS phases 1-3 to refine our “dissemination playbook” that guides adoption by other school systems (EPIS Phase 4). Our primary implementation hypothesis is: Reach will be greater among students when delivered using the BACK-E arm as compared to BACK-S. Our effectiveness hypothesis is: BACK will be more effective than usual care at reducing asthma exacerbations. The BACK playbook includes training materials and a calculation of return on investment. The investigators are targeting schools with high levels of uncontrolled asthma and asthma associated burden. Our UH3 trial includes partner engagement to ensure BACK is disseminated to diverse geopolitical areas of Colorado with attention to sustainability. Collectively, our approach will accelerate dissemination of BACK nationally to communities experiencing health inequities in pediatric asthma care.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU<\/h4>\n

        Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU. The goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care. Participants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        The Effect of Deep Tissue Massage on Respiratory Parameters in People With Asthma<\/h4>\n

        Bronchial asthma, as a chronic inflammatory disease of the respiratory tract, significantly reduces the quality of life of patients. Standard treatment includes pharmacotherapy, but a holistic approach, including manual therapies, can support pharmacological therapy, reducing the need for drugs. The aim of the research is to verify whether deep tissue massage (DTM) techniques applied to the chest significantly affect respiratory parameters in people with asthma. The study is the next stage of the study conducted on healthy people. After obtaining positive results in the study involving people not suffering from respiratory diseases, the next step is to examine people with, in this case, bronchial asthma. It is important to determine whether the use of this form of manual therapy can bring benefits in the context of improving respiratory functions, reducing respiratory muscle tension and relieving subjective symptoms associated with asthma, such as shortness of breath or limitations in everyday functioning. The hypothesis assumes that DTM techniques can have a bigger effect on the respiratory system than classic massage (CM). The study is a randomized controlled trial, where participants will be randomly assigned to one of two groups: the study group (subjected to DTM) or the control group (subjected to CM). Before and after the massage intervention, participants will undergo spirometry to assess the changes in respiratory parameters. The obtained data will then be analyzed for effects on respiratory parameters and differences between both groups.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        LIving BEtteR With asThma studY:: A Multimodal Intervention to Address Multimorbidity in Difficult Asthma<\/h4>\n

        Multimorbidity is a significant issue for many patients with difficult asthma. With patients, we have co-designed a multimodal intervention comprising prescribed exercise, dietary support, breathing pattern retraining and behaviour change to target multimorbidity in difficult asthma<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab<\/h4>\n

        This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Reducing Overuse of Antibiotics With Decision Support<\/h4>\n

        Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children’s hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children’s hospitals.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma<\/h4>\n

        Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Viral Infection in Asthma (VIA) Study<\/h4>\n

        Often when people with asthma get a virus caused by the common cold (rhinovirus), they also experience an increase or worsening of their asthma symptoms. The purpose of this study is to see if the study medication dupilumab helps prevent those with mild to moderate asthma from having increased asthma symptoms, after being exposed to an experimental rhinovirus inoculation. This is a study about dupilumab which is a drug approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate to severe asthma. Dupilumab is a medication that blocks pathways that cause asthmatic inflammation in the lungs, leading to symptoms and worsening lung function. During this study, subjects will be given either dupilumab or placebo and will subsequently be exposed to the the “common” cold virus (rhinovirus). The virus that the investigators are using has been safely used before in many studies like this involving thousands of volunteers, and the safe use of the virus in this research study has been reviewed by the FDA. The investigators will track asthma symptoms during the study with lung function tests, questionnaires, specimen collection, biomarkers, and physical exams. For data analysis the investigators will assess the samples collected to determine changes in the treatment groups. The investigators will also asses the symptom scores and deviations from baseline measures for lung function.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        A Study of CDX-622 in Participants With Mild to Moderate Asthma<\/h4>\n

        This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n

        Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department<\/h4>\n

        This study aims to compare the efficacy of a one-time IM dose of dexamethasone versus a 5-day course of prednisone in adult ED patients presenting with asthma exacerbations. This is a randomized, controlled, double-blind, non-inferiority trial conducted at two urban EDs within the Montefiore Health System.<\/p>\n\n PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n <\/a>

        \n
        \n\n\n

        <\/p>\n","protected":false},"excerpt":{"rendered":"

        If you\u2019ve ever woken up congested, sneezed nonstop through the night, or dealt with scratchy, watery eyes all year long, you\u2019re likely familiar with allergic “Can a Natural Nasal Spray Block Dust Mite Allergy Flare-Ups? Inside the ACARAY Clinical Trial”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[],"class_list":["post-72893","post","type-post","status-publish","format-standard","hentry","category-bronchialasthma"],"_links":{"self":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts\/72893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72893"}],"version-history":[{"count":4,"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts\/72893\/revisions"}],"predecessor-version":[{"id":72897,"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts\/72893\/revisions\/72897"}],"wp:attachment":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}